HKEX:1477 - Ocumension Therapeutics Ocumension Therapeutics
Sector: Health Care, Industry: Biotechnology
Add to Watchlist
   
Add Alert 


Yahoo Finance

HKD 17.94    +0.160 (+0.90%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

26 Nov 2021


Loading...
Loading...
Loading...

General

CEO: Mr. Ye Liu

Headquarters: HK

Employees: 187

Homepage

Description

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.